Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Arquivos Brasileiros de Endocrinologia & Metabologia (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302013000200005 |
Resumo: | OBJECTIVE: The purpose of this study was to identify factors that might interfere with reaching the final height in patients with 21-hydroxylase deficiency (21-OHD). SUBJECTS AND METHODS: Thirty-one patients with classical 21-OHD who reached their FH in our Institution were evaluated in order to compare the Z score for final height (FHZ) with: (1) the target height, (2) the standard height for the population, and (3) the hydrocortisone treatment schedule. RESULTS: The FHZ of -2.13 ± 1.11 had a significant negative correlation with the hydrocortisone doses used throughout the period of study. Patients who reached FH within the normal population range were those who received lower doses of hydrocortisone, as compared to those whose FH remained below -2 SDS. CONCLUSION: We conclude that careful treatment adjustments have a major influence on growth of children with CAH, and that the dose range for hydrocortisone replacement that does not lead to side effects is relatively narrow. The better height outcome was achieved in 21-OHD patients who received lower doses of hydrocortisone. |
id |
SBEM-2_f5861ae21fda11af53c5c692faeede54 |
---|---|
oai_identifier_str |
oai:scielo:S0004-27302013000200005 |
network_acronym_str |
SBEM-2 |
network_name_str |
Arquivos Brasileiros de Endocrinologia & Metabologia (Online) |
repository_id_str |
|
spelling |
Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenismCongenital adrenal hyperplasiasteroid 21-hydroxylasecorticosteroidshydrocortisonebody heightOBJECTIVE: The purpose of this study was to identify factors that might interfere with reaching the final height in patients with 21-hydroxylase deficiency (21-OHD). SUBJECTS AND METHODS: Thirty-one patients with classical 21-OHD who reached their FH in our Institution were evaluated in order to compare the Z score for final height (FHZ) with: (1) the target height, (2) the standard height for the population, and (3) the hydrocortisone treatment schedule. RESULTS: The FHZ of -2.13 ± 1.11 had a significant negative correlation with the hydrocortisone doses used throughout the period of study. Patients who reached FH within the normal population range were those who received lower doses of hydrocortisone, as compared to those whose FH remained below -2 SDS. CONCLUSION: We conclude that careful treatment adjustments have a major influence on growth of children with CAH, and that the dose range for hydrocortisone replacement that does not lead to side effects is relatively narrow. The better height outcome was achieved in 21-OHD patients who received lower doses of hydrocortisone.Sociedade Brasileira de Endocrinologia e Metabologia2013-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302013000200005Arquivos Brasileiros de Endocrinologia & Metabologia v.57 n.2 2013reponame:Arquivos Brasileiros de Endocrinologia & Metabologia (Online)instname:Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)instacron:SBEM10.1590/S0004-27302013000200005info:eu-repo/semantics/openAccessCordeiro,Giovana VignoliSilva,Ivani NovatoGoulart,Eugênio Marcos AndradeChagas,Antônio José dasKater,Cláudio Eliaseng2013-03-19T00:00:00Zoai:scielo:S0004-27302013000200005Revistahttps://www.aem-sbem.com/ONGhttps://old.scielo.br/oai/scielo-oai.php||abem-editoria@endocrino.org.br1677-94870004-2730opendoar:2013-03-19T00:00Arquivos Brasileiros de Endocrinologia & Metabologia (Online) - Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)false |
dc.title.none.fl_str_mv |
Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism |
title |
Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism |
spellingShingle |
Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism Cordeiro,Giovana Vignoli Congenital adrenal hyperplasia steroid 21-hydroxylase corticosteroids hydrocortisone body height |
title_short |
Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism |
title_full |
Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism |
title_fullStr |
Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism |
title_full_unstemmed |
Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism |
title_sort |
Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism |
author |
Cordeiro,Giovana Vignoli |
author_facet |
Cordeiro,Giovana Vignoli Silva,Ivani Novato Goulart,Eugênio Marcos Andrade Chagas,Antônio José das Kater,Cláudio Elias |
author_role |
author |
author2 |
Silva,Ivani Novato Goulart,Eugênio Marcos Andrade Chagas,Antônio José das Kater,Cláudio Elias |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Cordeiro,Giovana Vignoli Silva,Ivani Novato Goulart,Eugênio Marcos Andrade Chagas,Antônio José das Kater,Cláudio Elias |
dc.subject.por.fl_str_mv |
Congenital adrenal hyperplasia steroid 21-hydroxylase corticosteroids hydrocortisone body height |
topic |
Congenital adrenal hyperplasia steroid 21-hydroxylase corticosteroids hydrocortisone body height |
description |
OBJECTIVE: The purpose of this study was to identify factors that might interfere with reaching the final height in patients with 21-hydroxylase deficiency (21-OHD). SUBJECTS AND METHODS: Thirty-one patients with classical 21-OHD who reached their FH in our Institution were evaluated in order to compare the Z score for final height (FHZ) with: (1) the target height, (2) the standard height for the population, and (3) the hydrocortisone treatment schedule. RESULTS: The FHZ of -2.13 ± 1.11 had a significant negative correlation with the hydrocortisone doses used throughout the period of study. Patients who reached FH within the normal population range were those who received lower doses of hydrocortisone, as compared to those whose FH remained below -2 SDS. CONCLUSION: We conclude that careful treatment adjustments have a major influence on growth of children with CAH, and that the dose range for hydrocortisone replacement that does not lead to side effects is relatively narrow. The better height outcome was achieved in 21-OHD patients who received lower doses of hydrocortisone. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013-03-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302013000200005 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302013000200005 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S0004-27302013000200005 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Endocrinologia e Metabologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Endocrinologia e Metabologia |
dc.source.none.fl_str_mv |
Arquivos Brasileiros de Endocrinologia & Metabologia v.57 n.2 2013 reponame:Arquivos Brasileiros de Endocrinologia & Metabologia (Online) instname:Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) instacron:SBEM |
instname_str |
Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) |
instacron_str |
SBEM |
institution |
SBEM |
reponame_str |
Arquivos Brasileiros de Endocrinologia & Metabologia (Online) |
collection |
Arquivos Brasileiros de Endocrinologia & Metabologia (Online) |
repository.name.fl_str_mv |
Arquivos Brasileiros de Endocrinologia & Metabologia (Online) - Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) |
repository.mail.fl_str_mv |
||abem-editoria@endocrino.org.br |
_version_ |
1754734812233465856 |